The immunomodulator pyran markedly protected 5-week-old mice from lethal intravenous infection with herpes simplex virus type 2. The 50% lethal dose was increased almost 100-fold in pyran-treated mice as compared with controls. Although the protection was not as marked in older mice (10 and 16 weeks old), there was a significant increase in mean survival time. When the pathogenesis ofherpesvirus disease was monitored in control and drug-treated mice, the effect of pyran was most evident in the spinal cord, where virus was recovered from 20 of 25 control mice and from only 6 of 25 pyran-treated mice. There was also a significant reduction in the titer of virus present, and virus appeared later in the spinal cord of pyran-treated mice than in control mice. The protective effect of pyran was observed only when the drug was administered 24 h before viral challenge, was seen after both intraperitoneal and intravenous injection, and was not due to direct inactivation of the virus. Adequate antiviral chemotherapy is not available for herpesvirus infections such as herpes encephalitis, herpes zoster, or herpes labialis or genitalis. The results of recent clini-
Anmther synthetic polyanion, pyran, a copolymer of maleic anhydride and divinyl ether, profoundly alters the reticuloendothelial system (25) and various immunological responses (2, 24) and induces interferon (21) . Pyran has been shown to be an effective antiviral agent against 28 several ribonucleic acid viruses, including vesicular stomatitis virus (12) , foot-and-mouth disease virus (30) , encephalomyocarditis (24) and mengovirus (20) , ribonucleic acid leukemia viruses (10, 22, 29) , and one deoxyribonucleic acid virus, vaccinia (11) . We have previously demonstrated that pyran is protective against intravenous or intravaginal infection of mice with herpes simplex virus type 2 (HSV-2) (23) . In the present study, we examined the effect of varying the route and the time of administration of the drug and monitored the effect of pyran on the pathogenesis of systemic herpesvirus disease.
(This paper was presented in part at the 75th Annual Meeting of the American Society for Microbiology, New York, 27 April to 2 May 1975.) MATERIALS AND METHODS Mice. Female BALB/c mice (Flow Rdsearch Animals, Inc., Dublin, Va., and Laboratory Supply, Indianapolis, Ind.) were received at 4 to 5 weeks of age and usually were used for experiments at 5 to 6 weeks of age.
Cells. HEp-2 cells (Microbiological Associates, Bethesda, Md.) and Vero cells (courtesy of Byron Murray) were grown in Eagle minimal essential medium with Hanks balanced salt solution (HMEM), 10% heat-inactivated fetal calf serum, and no antibiotics. For virus titrations, HMEM with 2% fetal calf serum, 1% methyl cellulose, 200 U of penicillin per ml, 100 ,ug of streptomycin per ml, and 1 Virus. The virus used in this study was a recent human isolate identified as HSV-2 by the indirect hemagglutinin test (courtesy of John Stewart, Center for Disease Control, Atlanta Ga.). Virus was propagated in HEp-2 cells and had a titer of 5 x 106 plaque-forming units (PFU)/ml. Virus titrations. Virus was titrated for PFU on cells grown in 24-well tissue culture plates (Linbro Chemical Co., New Haven, Conn.). The virus-infected cells were incubated for 2 days, and cells were stained with crystal violet to visualize plaques. Virus titrations were performed on HEp-2 cells, except where indicated.
Drugs. Pyran, a polyanionic copolymer of maleic anhydride and divinyl ether, lot XA 124-177, was obtained from David Breslow, Hercules, Inc., Wilmington, Del. The drug was solubilized in 0.15 N NaCl brought up to pH 7.0 with NaOH.
Animal experiments. Groups of 10 mice were injected with pyran intravenously (i.v.) (0.5 mg/ mouse) or intraperitoneally (i.p.) (1.5 mg/mouse) and infected with virus 24 h later. These doses are similar to those reported effective against other viruses (20, 24) and are not toxic. The acute mean lethal dose (LD50) is approximately 1.5 mg/mouse by i.v. injection. Mice were checked daily for mortality and the percent mortality was calculated. The majority of deaths occurred within 14 days after infection, and all had occurred by 25 days. The mean survival time was calculated using 25 days as the day of death for the surviving mice. Statistical analysis of mortality data was performed using the chi-square test with Yates' correction factor, and mean survival time was evaluated by the Student's t test. For some experiments, groups of 10 animals were infected with several 10-fold dilutions of virus, and the PFU required for the LD50 was calculated by the method of Reed and Muench (28) .
Pathogenesis studies. Mice were treated with 0.15 N NaCl or drug and infected as described. Groups of five control or drug-treated mice were sacrificed on various days after infection, organs were removed, and the individual samples were triturated in mortars. Blood, kidney, spleen, liver, spinal cord, cerebellum and brain stem, and cerebrum were collected from each animal, and the clinical status of the animal (well, hunched with ruffled fur, paralyzed, moribund) was noted. Ten percent (wt/vol) suspensions of all organs, except spinal cord and blood, were prepared in viral diluent containing Hanks balanced salt solution, 0.5% gelatin, 0.25% lactalbumin hydrolysate, and antibiotics. Spinal cord was prepared as a 5% suspension, and clotted blood was prepared as a 33% suspension. Specimens were centrifuged at 1,000 x g, and the supernatant fluids were frozen at -70 C until the separate specimens from individual mice were assayed for virus by plaque formation on Vero cells.
RESULTS
Antiviral action of pyran in mice of various ages. A marked age-related resistance to systemic infection with HSV has been noted to occur in mice between birth and 4 weeks of age (15, 16) . Experiments were performed to determine whether this age-related resistance continued to increase in early adulthood and to follow the antiviral effects of pyran during this period. The LDO of HSV-2 increased 50-fold between 5 and 10 weeks of age and remained relatively constant thereafter (Table 1) . Prophylactic treatment with pyran markedly protected 5-week-old mice from HSV-2 lethality; the LD50 was increased 80-fold, from 101.4 PFU in control animals to 103-3 PFU in pyran-treated animals. Although the protective effects of pyran were not as marked in the 10-and 16-week-old mice, the LD50 was increased four-to eightfold, and the mean survival time of mice was significantly increased over controls. Although the older mice were larger, the milligrams per kilogram dose ranged from only 25 to 33 mg/kg, both dosages which we have shown to be effective in older mice.
Effect of pyran on HSV-2 pathogenesis. To follow quantitatively the course of HSV-2 infection in control and drug-treated 5-week-old animals, organs from individual mice whose clinical status was noted were collected at various times during infection and assayed individually for virus. Groups of 10 control and drug-treated mice were followed for mortality. In this experiment prophylactic i.v. treatment with pyran reduced the mortality from 8/lo in control mice to l/1o in pyran-treated mice.
No virus was detected in any samples of blood, spleen, or liver assayed between days 1 and 13 after i.v. virus infection. However, low levels of virus (less than 103 PFU/g) were sporadically detected in the kidney in 2 of 25 samples from control mice and in 6 of 25 samples from pyran-treated mice harvested on days 6 to 13 after infection. Amounts of virus in the cerebellum-brain stem reached peak mean titers of less than 102 PFU/g between days 8 and 11 in both control and drug-treated groups. A titer of 10 PFU/g of cerebral tissue was observed in only one drug-treated mouse on day 11 after infection.
The effect of pyran treatment on the pathogenesis-of HSV-2 was most evident in the spinal cord. The geometric mean titers of virus present in the spinal cord were significantly reduced in drug-treated as compared with control mice on days 6 through 10 after infection (Fig.  1) . Furthermore, virus was recovered from the spinal cord in 20 of 25 control mice and from only 6 of 25 pyran-treated mice that were sacrificed between days 6 and 13 after virus infection. Virus also appeared later in the drugtreated mice. A level of 3 x 103 PFU/g of tissue was observed on day 6 in control animals, VOL. 10, 1976 on September 26, 2017 by guest http://aac.asm.org/ (20) . However, when HSV-2 was mixed with varying concentrations of pyran in vitro for 1 h at 36 C, there was little loss in infectivity ( Table 2) . Concentrations of 12.5 mg of pyran per ml were required to reduce the virus titer one log,0.
Since mice were treated with 0.5 mg, it seemed unlikely that direct inactivation of the virus could account for the antiviral effect of the drug. However, it was possible that pyran could be altered in vivo to an active inhibitory form. Serum and 10% spleen homogenates were prepared from mice 24 h after i.v. injection with pyran, at the time when mice were protected in vivo against i.v. challenge with virus. These serum and spleen homogenates did not directly inactivate HSV-2 in vitro (data not shown).
Effect of varying the route of administration of pyran. The antiviral effect ofpolyanions has been reported to be a primarily local effect (20) (Table 3 ) and in increasing the mean survival time of mice (data not shown).
Effect of varying the time of administration of pyran. The protective effect of pyran was limited with respect to the time of drug administration relative to viral inoculation. Marked protection against virus lethality was observed only when pyran was administered 24 h before viral challenge (Table 4) .
Effect of pinworm infestation on HSV-2 infection and pyran protection. Evidences of either pinworm infestation or Pasteurella pneumotropica infection of the brain were observed in certain shipments of mice. To determine whether pinworm infestation affected experiments, pinworm-infested and pinworm-free mice were treated with pyran and infected with HSV-2. Half of one shipment of mice was treated orally with piperazine (11 mg of piperazine citrate per ml of drinking water) for 2 weeks until tlhey were found to be completely pinworm free, whereas the pinworm-infested mice were housed normally but kept isolated from other mice. Pinworm infestation did not markedly affect the HSV-2 infection (Table 5) . Although pyran appeared to be equally effective in pinworm-free and -infested mice at day 17 7/14e 10/14 15.9 ± 1.0 a Pinworm-free and -infested 6-week-old mice were treated i.v. with pyran (0.5 mg/mouse) 24 h before i.v. challenge with HSV-2 (103.0 PFU).
8 Mean survival time ± standard error.
ep < 0.05.
tration was essential for activity against HSV-2 infection, as has been previously reported for activity against mengovirus infection (20) . Merigan and Finkelstein (20) showed that 1 to 5 mg/ml reduced plaque formation by mengovirus, vesicular stomatitis virus, and vaccinia virus; the authors concluded that direct virus inactivation was unlikely to account for the in vivo protection. With the HSV-2 used in the present studies, a dose of 10 mg/ml was required to reduce virus titer by one log,0. These results are consistent with the previous data. The slight difference in amount of drug required for direct inactivation may reflect differences in viruses or the source of drug. Pyran has been demonstrated to be a potent inhibitor of ribonucleic acid-dependent deoxyribonucleic acid polymerase in vitro and to slightly inhibit alpha-and beta-mammalian polymerases (27 
78).
It would be tempting to suggest interferon involvement in this early antiviral effect. However, there is no compelling evidence for a significant role for interferon in the antiviral effects of pyran. We have previously demonstrated that the antiviral effect of pyran against encephalomyocarditis virus was not correlated with induction of interferon (24) . Similar conclusions were reached by Billiau et al. concerning the antiviral action of another polyanion, chlorite-oxidized oxyamylose, against mengovirus infection (5). The authors postulated that the antiviral effect might be related to macrophage activation in the peritoneal cavity. The fact that herpesviruses are generally among the most resistant to the antiviral effects of interferon also argues against an important role for interferon.
Pyran is an immunoadjuvant for certain humoral immune responses (2) . However, we have seen no evidence for increased neutralizing antibody production in pyran-treated as compared with untreated mice (Breinig et al., Abstr. Annu. Meet. Am. Soc. Microbiol. 1976, E88, p. 78). Cell-mediated immunity has been implicated as important in recovery of animals from primary herpesvirus infections (7, 32) , but we have shown that pyran was effective against HSV-2 in mice depleted of thymus-derived lymphocytes by adult thymectomy, lethal irradiation, and bone marrow reconstitution (23) . These data suggest that pyran may exert its antiviral activity not through modulation of specific immunological responses toward HSV-2 but by activating macrophages for enhanced nonspecific antiviral activity. The increased efficacy of the drug in 5-week as compared with 15-week-old mice may have some bearing on this point. Hirsch 
